Factors that May Influence the Choice of Antiplatelet Therapy: A Clinical Case Discussion and Current Guidelines

Title:

Factors that May Influence the Choice of Antiplatelet Therapy: A Clinical Case Discussion and Current Guidelines

Topic: Cardiology
Relevant Terms: Acute Coronary Syndrome, Antiplatelet Therapies
Primary Audience: Cardiologists, Interventional Cardiologists and other healthcare professionals interested in the management of patients with ACS.
Launch Date: 22-Mar-12
Credits: 0.25 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Hot Topics in the Management of Patients with Acute Coronary Syndromes: A Clinical Case...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Evaluate the potential influence of genetic polymorphisms and of drug-drug interactions on the choice of antiplatelet therapy.

    Faculty

    Deepak L. Bhatt, MD, MPH
    Chief of Cardiology, VA Boston Healthcare System
    Director, Integrated Interventional Cardiovascular Program
    Brigham and Women's Hospital and VA Boston Healthcare System
    Senior Investigator, TIMI Study Group
    Associate Professor of Medicine, Harvard Medical School
    Boston, Massachusetts
    Christopher P. Cannon, MD
    Senior Investigator, TIMI Study Group
    Cardiovascular Division, Brigham and Women's Hospital
    Professor of Medicine, Harvard Medical School
    Boston, Massachusetts
    Estimated time to complete activity: 15 minutes

    Program Overview
    Antiplatelet therapies are the cornerstone of treatment for patients with acute coronary syndrome (ACS) or those undergoing percutaneous coronary intervention (PCI). However, despite many advances and complex treatment regimens, patients with ACS continue to be at significant risk of morbidity and mortality, indicating the need for improved performance on the use of antiplatelet therapy. Some of the hot topics in this field include optimal dosing and duration for antiplatelet regimens, response variability, potential drug-drug interactions, and poor adherence to guideline-recommended therapy. There is an urgent educational need to keep healthcare professionals updated with the current guideline recommendations and also to elucidate how new and emerging data can be incorporated into clinical practice.
     
    A clinical case-based discussion will be used to highlight current guideline recommendations on the use of antiplatelet therapies; current clinical trial data on newer antiplatelet therapies; and strategies for choosing optimal therapy based on patient characteristics. The second case will highlight the role of genetic testing, platelet function testing, and potential drug-drug interactions on the choice of antiplatelet therapy.

    Target Audience
    This activity is designed for cardiologists, interventional cardiologists and other healthcare professionals who are interested in the management of patients with ACS.

    Physician Continuing Medical Education
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    The Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The program will be designed as 2 activities (0.25 credits for each 15 minute case). Participants may receive credit for each case.

    Disclosure of Conflicts of Interest
    The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Dr. Cannon serves on the advisory board (funds donated to charity) for: Bristol-Myers Squibb/sanofi-aventis Partnership; Novartis International AG; Alnylam Pharmaceuticals, Inc. He is a clinical advisor and holds equity in Automedics Medical Systems. He conducts contracted research for: Accumetrics, Inc.; AstraZeneca; GlaxoSmithKline; Essentialis, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc. He develops independent educational symposia for: Pfizer, Inc.; AstraZeneca.
     
    Dr. Bhatt
     conducts contracted research for: Amarin Pharma Inc.; AstraZeneca; Bristol-Myers Squibb; Eisai Inc.; Ethicon, Inc.; Medtronic; sanofi-aventis; The Medicines Company.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    The following ACCELMED planners and managers Jason LeDune and Jason Xu, hereby state no relationships with commercial interests; and Janardhan Sampath, PhD is married to an employee of Bristol-Myers Squibb.
     
    Request for Credit
    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
     
    Media
    Internet
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ACCELMED and RealCME do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ACCELMED, and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
     
    PIM Web site: www.pimed.com
     
    Acknowledgement




    This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC